NasdaqCM - Nasdaq Real Time Price USD

Vincerx Pharma, Inc. (VINC)

Compare
0.1926 +0.0016 (+0.84%)
At close: December 16 at 4:00:00 PM EST
0.1943 +0.00 (+0.88%)
After hours: 7:46:20 PM EST

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Ahmed M. Hamdy M.D. Co-Founder, Chairman & CEO 657.54k -- 1965
Dr. Raquel E. Izumi Ph.D. Co-Founder, President, COO, Secretary & Director 591.54k -- 1969
Mr. Alexander A. Seelenberger M.B.A. Chief Financial Officer 491.69k -- 1979
Mr. Tom C. Thomas J.D. Founder, General Counsel & Chief Legal Officer 444.14k -- 1960
Dr. John C. Byrd M.D. Founder & Chairman of Scientific Advisory Board -- -- --
Dr. Hans-Georg Lerchen Ph.D. Chief Scientific Officer -- -- --
Ms. Gabriela Jairala Vice President of Investor Relations & Corporate Communications and Chief of Staff -- -- --
Ms. Karen Quarford M.B.A. Vice President of Quality Operations & Compliance -- -- --
Ms. Melissa Merrick SPHR Senior Director of People & Culture and Head of Human Resource -- -- --
Dr. Beatrix Stelte-Ludwig Ph.D. Executive Chief Development Officer -- -- --

Vincerx Pharma, Inc.

260 Sheridan Avenue
Suite 400
Palo Alto, CA 94306
United States
650 800 6676 https://vincerx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
42

Description

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.

Corporate Governance

Vincerx Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 12, 2024 at 2:00 PM UTC

Vincerx Pharma, Inc. Earnings Date

Recent Events

December 10, 2024 at 12:00 AM UTC

DEF 14A: Proxy Statements

December 6, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 25, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 14, 2024 at 12:00 AM UTC

SC 13G/A: Tender Offer/Acquisition Reports

November 12, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 5, 2024 at 12:00 AM UTC

PRE 14A: Proxy Statements

October 7, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 30, 2024 at 12:00 AM UTC

SC TO-I/A: Tender Offer/Acquisition Reports

September 10, 2024 at 12:00 AM UTC

SC TO-I/A: Tender Offer/Acquisition Reports

August 19, 2024 at 12:00 AM UTC

SC TO-I/A: Tender Offer/Acquisition Reports

Related Tickers